Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Inclusion Criteria: * 5 Years to 70 Years, Male and female; * Expected survival \> 12 weeks; * Performance score 0-2; * Histologically confirmed as CD19-positive lymphoma/leukemia and who meet one of the following conditions; Patient receive at least 2-4 prior combination chemotherapy regimens (not including single agent monoclonal antibody therapy) and fail to achieve CR; or have disease recurrence; or not eligible for allogeneic stem cell transplantation; or disease responding or stable after most recent therapy but refused further treatment; Disease recurrence after stem cell transplantation; Diagnosis as lymphoma, but refuse conventional treatment such as chemotherapy, radiation, stem cell transplantation and monoclonal antibody therapy * Creatinine \< 2.5 mg/dl; * ALT/AST \< 3x normal; * Bilirubin \< 2.0 mg/dl; * Adequate venous access for apheresis, and no other contraindications for leukapheresis; * Take contraceptive measures before recruit to this trial; * Written voluntary informed consent is given. Exclusion Criteria: * Patients with symptoms of central nervous system * Accompanied by other malignant tumor * Active hepatitis B or C, HIV infection * Any other diseases could affect the outcome of this trial * Suffering severe cardiovascular or respiratory disease * Poorly controlled hypertension * A history of mental illness and poorly controlled * Taking immunosuppressive agents within 1 week due to organ transplantation or other disease which need long-lasting administration * Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment * Reaching a steady dose if receiving anticoagulant therapy before assignment * Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion * Pregnant or lactating women * Subject suffering disease affects the understanding of informed consent or comply with study protocol.